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Acute myeloid leukemia (AML) therapy involves
compounds that are cytotoxic to both normal
and cancer cells, and relapsed AML is resistant
to subsequent chemotherapy. Thus, agents are
needed that selectively kill AML cells with minimal
toxicity. Here, we report that AML is dependent
on DDX5 and that inhibiting DDX5 expression
slows AML cell proliferation in vitro and AML pro-
gression in vivo but is not toxic to cells from
normal bone marrow. Inhibition of DDX5 expres-
sion in AML cells induces apoptosis via induction
of reactive oxygen species (ROS). This apoptotic
response can be blocked either by BCL2 overex-
pression or treatment with the ROS scavenger
N-acetyl-L-cysteine. Combining DDX5 knockdown
with a BCL2 family inhibitor cooperates to induce
cell death in AML cells. By inhibiting DDX5 expres-
sion in vivo, we show that DDX5 is dispensable for
normal hematopoiesis and tissue homeostasis.
These results validate DDX5 as a potential target
for blocking AML.
INTRODUCTION
Acute myeloid leukemia (AML) is a disease in which the
differentiation of hematopoietic progenitor cells is blocked,
resulting in unregulated expansion of leukemic blasts that
is rapidly fatal if untreated. The average age of onset of
AML is 66 years, and the 2-year survival rate for patients
older than 56 years is 20%–25% (Estey and Do¨hner, 2006).
AML chemotherapy is not selective because it kills normal he-
matopoietic cells and presents a challenge for treatment,
particularly in elderly patients with AML, due to toxicity. More-
over, chemotherapy-resistant AML with unfavorable cytoge-
netics is markedly prevalent in elderly patients (Yanada and
Naoe, 2012). Hence, there is a strong demand for new drug tar-
gets that when inhibited will selectively block AML without
toxicity.CThe DEAD-box RNA helicase, DDX5, is a multifunctional
protein with an important role in transcription regulation with
multiple, sequence-specific transcription factors (Fuller-Pace,
2013) but has been implicated in other processes such asmicro-
RNA biology, RNA splicing, and ribosome biogenesis (Dardenne
et al., 2012; Davis et al., 2008; Fukuda et al., 2007; Saporita et al.,
2011). DDX5 is frequently overexpressed in colon, breast, and
prostate cancer as well as T cell acute lymphoblastic leukemia
(T-ALL) (Causevic et al., 2001; Clark et al., 2008; Lin et al.,
2013; Shin et al., 2007; Wortham et al., 2009). Previously, we
reported that DDX5 functions as a transcriptional coactivator
for E2F1 to promote the expression of genes required for cell
proliferation and that Ddx5 is frequently amplified in addition to
being overexpressed in breast cancer (Mazurek et al., 2012).
DDX5 knockdown in breast cancer cells with Ddx5 gene amplifi-
cation blocked their proliferation and resulted in downregulated
expression of DNA replication factors. In contrast, DDX5 knock-
down in breast cancer cells lacking Ddx5 gene amplification did
not affect the expression of DNA replication factors, and these
cells continued to proliferate. Thus, epithelial breast cancers
that overexpress DDX5 exhibit a greater dependence on DDX5
to proliferate than breast cancers that do not overexpress
DDX5. Recently, a requirement for DDX5 in proliferation of
T-ALL cells was described by Lin et al. (2013). In these cells,
DDX5 interacts with MAML1 to promote the expression of
NOTCH-regulated genes; however, this study showed that
DDX5 is required for initiation of T-ALL in vivo, but it remains un-
clear whether DDX5 inhibition slows progression of established
T-ALL or any other cancer.
Here, we report results that demonstrate a dependence
on DDX5 for proliferation of human AML cells containing
various genetic lesions. Using a mouse model for chemo-
therapy-resistant AML, we demonstrate that inhibition of
DDX5 expression slows progression of established AML in vivo.
Moreover, we developed transgenic mouse lines with doxycy-
cline-inducible, systemic expression of a potent DDX5 small
hairpin RNA (shRNA) and found that DDX5 depletion did not
adversely affect either bone marrow function or adult mouse
physiology. These results are consistent with an acquired
dependence of AML cells on DDX5 and suggest that DDX5
inhibitors should be effective against AML and well tolerated
by normal tissues.ell Reports 7, 1887–1899, June 26, 2014 ª2014 The Authors 1887
RESULTS
Human AML Cell Lines Are Dependent on DDX5 to
Proliferate
We investigated whether the ability of AML cell lines to proliferate
was dependent on DDX5 bymeasuring the effect of DDX5 deple-
tion on cell proliferation over time after retroviral-mediated
shRNA transduction into the cells. Retroviruses encoding either
of two potent DDX5 shRNAs (shDDX5.2008 or shDDX5.2053) or
a control shRen.713 shRNA (targeting Renilla luciferase), each
linked to GFP, were transduced into AML cell populations that
also included GFP-negative cells to enable direct comparison
in the same culture of the proliferative fitness of DDX5-express-
ing and depleted cells. DDX5 knockdown impaired proliferation
of seven of eight human AML cell lines having different onco-
genic driver mutations (Figures 1 and S1A). Only one cell line,
Eol-1, was resistant to DDX5 knockdown (Figure S1B). Immuno-
blot analysis of DDX5 in these eight AML cell lines did not reveal a
correlation between DDX5 expression and sensitivity to DDX5
depletion (Figure S1C). These results suggest a broad depen-
dency of genetically diverse human AML cell lines on DDX5 to
proliferate in a manner independent of DDX5 protein levels.
DDX5 Is Required for AML Progression In Vivo
The dependence of DDX5 for AML progression in vivo was
tested using a mouse model of AML (Zuber et al., 2011a,
2011b). AML is driven by the expression of an MLL-AF9 fusion
protein together with constitutively active NRASG12D (Zuber
et al., 2011a). The AML cells used in this model express the
reverse tetracycline transactivator (rtTA), allowing doxycycline-
induced gene knockdown following transduction of the AML
cells with a vector encoding a shRNA downstream of a tetracy-
cline-responsive promoter. AML-harboring Mll translocations
exhibit partial differentiation along the monocytic lineage, and
patients with AML with these mutations have a poor prognosis
(Schoch et al., 2003). Similar to human Mll-translocated AML,
leukemia that develops in this mouse AMLmodel also expresses
surface protein markers consistent with partial monocytic differ-
entiation and is refractory to Ara-C chemotherapy (Zuber et al.,
2009). Importantly, following AML cell transplantation into recip-
ient mice, leukemia develops with normal expression of the
shRNA target gene. Once leukemia is established, as deter-
mined by bioluminescence imaging, the mice are given doxycy-
cline in their food and water to induce expression of the shRNA
and knockdown of the shRNA target. The effect of target inhibi-
tion on progression of established AML is then measured by
bioluminescence imaging and monitoring of animal survival
(Zuber et al., 2011a, 2011b).
Two independent murine Mll-Af9; NrasG12D AML cell lines
were tested here (RN2 and LG1) that were derived from the
spleens of terminally ill leukemic mice and cultured. The cells
were then infected with virus encoding either of two different
potent DDX5 shRNAs (shDDX5.1322 and shDDX5.2086) or the
control shRen.713 shRNA in which shRNA expression was either
constitutive (LG1 cell line series) or controlled by a doxycycline-
inducible promoter (RN2 cell line series). The competition pro-
liferation assay was applied to measure the effect of DDX5
knockdown on proliferation of LG1 cells. DDX5 knockdown by1888 Cell Reports 7, 1887–1899, June 26, 2014 ª2014 The Authorsboth DDX5 shRNAs substantially depleted LG1 cells in the cul-
tures (Figure 2A).
Clonal RN2 cells harboring doxycycline-inducible DDX5
shRNAs were derived and transplanted into sublethally irradi-
ated recipient mice (see Experimental Procedures). The RN2
cells constitutively express firefly luciferase to enable biolumi-
nescence imaging of leukemia onset and progression in mice
following transplantation. Five days following transplantation, a
relatively uniform leukemia signal was detected, and the mice
were separated into doxycycline-free or doxycycline-treated
treatment groups (indicated as Day 0 in Figure 2B). Doxycycline
induced expression of either the DDX5 experimental or Renilla
luciferase control shRNAs in the leukemia cells. Whereas leu-
kemia rapidly progressed to terminal stage within 7 days for
doxycycline-treated shRen.713 control mice, leukemia progres-
sion was significantly attenuated in the doxycycline-treatedmice
transplanted with RN2 cells expressing either of two different
DDX5 shRNAs (Figures 2B, S2A, and S2B). DDX5 knockdown
also significantly increased the length of mouse survival post-
transplantation (Figures 2C and S2C). These results indicate
that inhibition of DDX5 expression slows progression of estab-
lished AML in vivo.
Inhibition of DDX5 Expression Kills AML Cells by
Apoptosis
The mechanism by which AML cells are dependent on DDX5 to
proliferate was investigated in the RN2 AML cell line because
DDX5 knockdown in these cells was inducible and rapid (Fig-
ure 3A). Maximal DDX5 depletion was observed within 24 hr
following induction of shRNA expression.Within 48 hr of doxycy-
cline treatment, there was strong activation of both caspase-3
and caspase-8 indicating that DDX5 knockdown induced
apoptosis. This result was specific for cells with DDX5 knock-
down compared to the shRen.713 control shRNA. Moreover,
RN2 cells with DDX5 knockdown were rapidly selected against
in the cultures as evident by the reappearance of DDX5 signal
in the cultures expressing the DDX5 shRNA within 5 days after
doxycycline treatment, due to loss or silencing of the DDX5
shRNA. Similar experiments were performed in immortalized
mouse embryonic fibroblast (MEF) cells, and despite strong
DDX5 depletion in these cells, their proliferation was not
affected, and there was no activation of either caspase-3 or cas-
pase-8 (Figures S2D andS2E). These results indicate a cell-type-
specific DDX5 requirement in AML cells to promote cell survival.
The apoptotic response induced upon DDX5 knockdown was
independent of p53 activation (Figure S2F) but could be rescued
by overexpressing BCL2, as shown by measuring caspase
cleavage and Annexin V staining (Figures 3B and 3C). This result
implied that inhibition of DDX5 expression was activating
caspase-3 and caspase-8 via the intrinsic apoptotic pathway.
BCL2 stabilizes mitochondria and prevents cytochrome c
release to activate apoptosis; however, BCL2 should not inter-
fere with caspase-8 cleavage resulting from death receptor
activation. BCL2 overexpression blocked caspase-8 cleavage,
suggesting that this caspase was activated downstream of cyto-
chrome c release from the mitochondria rather than from death
receptor activation. Interestingly, BCL2 overexpression did not
completely rescue proliferation of the DDX5-depleted AML cells
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Figure 1. AML Cell Lines Are Dependent on DDX5 to Proliferate
The indicated AML cell lines were infected with retrovirus encoding GFP expression as well as either of two different DDX5 shRNAs (shDDX5.2008 or
shDDX5.2053; first and second lanes on each immunoblot, respectively) or a control shRNA targeting Renilla luciferase (RenLucif) (shRen.713; third lane on each
immunoblot). Immunoblots showDDX5 knockdown by the twoDDX5 shRNAs. On each immunoblot, whole-cell extracts (WCEs) prepared from cells infectedwith
the negative control shRen.713 were loaded at either equal total protein as the DDX5 knockdown WCEs (lane 3 on each immunoblot) or were diluted either 1:4
(lane 4 on each immunoblot) or 1:10 (lane 5 on each immunoblot) so that DDX5 knockdown by either shDDX5.2008 or shDDX5.2053 (lanes 1 and 2 on each
immunoblot) could be determined. Ponceau S-stained membranes are shown below each immunoblot to show protein loading. The effect of DDX5 knockdown
on proliferation of each cell line was determined bymonitoring the depletion of GFP-positive cells expressing the indicated shRNA in each unselected cell culture
following infection as described in Experimental Procedures. A reduction in GFP-positive cells over time indicates depletion of those cells expressing the
indicated shRNA from the cultures. The red and blue lines in each plot show the fate of cells expressing either the shDDX5.2008 or shDDX5.2053 experimental
shRNAs, respectively, whereas the black line in each plot shows the fate of cells expressing the shRen.713 control shRNA.(Figure 3D). Thus, DDX5 depletion slowed cell proliferation via a
non-BCL2-dependent mechanism in addition to inducing
apoptosis via a BCL2-dependent mechanism.
The dependence of the RNA helicase activity of DDX5 to pro-
liferate was investigated; however, RNAi-resistant Ddx5 trans-
genes could not be expressed in cancer cell lines (Mazurek
et al., 2012). Others have reported overexpression ofDdx5 trans-Cgenes expressing an N-terminal epitope tag (Shin et al., 2007),
and therefore, shDDX5.2008-resistant, Ddx5 transgenes encod-
ing either an HA- or 6myc-N-terminal tag were expressed. The
transgenes were either wild-type DDX5 or mutant DDX5 that
contained amino acid changes that block the RNA helicase
activity by abolishing either ATP binding (GNT) or ATP hydrolysis
(DQAD) (Jalal et al., 2007). Retroviral gene transfer was used toell Reports 7, 1887–1899, June 26, 2014 ª2014 The Authors 1889
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Figure 2. DDX5 Is Required for AML Progression In Vivo
(A) Mouse LG1 AML cells were infected with virus encoding GFP and either of two different shRNAs targeting murine DDX5 (shDDX5.1322 or shDDX5.2086) or
shRen.713. ShRNA expression in LG1 cells is constitutive following infection. Similar to Figure 1, WCEs prepared from LG1 cells transduced with shRen.713 are
loaded onto the immunoblot undiluted (lane 3), diluted 1:4 (lane 4), or 1:10 (lane 5), and WCEs from LG1 cells transduced with either shDDX5.1322 or
shDDX5.2086 are loaded in lanes 1 and 2, respectively. The immunoblot in the upper panel is detecting DDX5 protein expression, and the lower panel is the
Ponceau S-stained membrane to show protein loading in the wells. Cell proliferation was analyzed using the competition proliferation assay as described in
Figure 1. Data are presented as the mean from triplicate samples with SD shown.
(B) Clonal RN2 AML cells selected for either doxycycline-induced shDDX5.2086 or shRen.713 shRNA expression were transplanted by tail vein injection from
leukemic spleens into secondary recipient mice as described in Experimental Procedures. The AML cells constitutively express Firefly luciferase enabling
bioluminescence imaging of the transplanted leukemia cells in vivo. Day 0 indicated to the left of the bioluminescence imaging results indicates the time point
5 days after bone marrow transplantation with AML cells when leukemia was established in the mice, and they were separated into either doxycycline-treated or
untreated groups.
(C) Kaplan-Meier curves showing survival of mice transplanted with AML cells either induced or not induced to express the indicated shRNAs. Time zero on these
plots indicates the time point when the AML cells were transplanted into the mice. Doxycycline (DOX) was begun on day 5 posttransplantation as indicated by the
green arrows.transduce these N-terminally tagged, RNAi-resistant wild-type
or mutant Ddx5 transgenes into cancer cell lines. We could
detect stable HA- and 6myc-DDX5 expression in HCT116 cells.
Expression of HA-DDX5 was stronger than 6myc-DDX5 in these
cells (data not shown). Endogenous DDX5 was knocked down
by subsequently infecting these derivative HCT116 cell lines
with virus-encoding shDDX5.2008. Expression of the wild-type
and mutant RNAi-resistant DDX5 proteins was relatively uniform
after knockdown of endogenous DDX5 (Figure S3A). As ex-1890 Cell Reports 7, 1887–1899, June 26, 2014 ª2014 The Authorspected, knockdown of endogenous DDX5 impaired proliferation
of HCT116 cells (Figure S3B). Expression of RNAi-resistant wild-
type HA-DDX5 rescued HCT116 cell proliferation. However,
neither expression of the ATP binding nor ATP hydrolysis HA-
DDX5 mutants rescued HCT116 proliferation, suggesting that
RNA helicase activity of DDX5 was required for cancer cell
proliferation.
We were unable to obtain human AML cell lines that stably
expressed either the untagged or N-terminal-tagged Ddx5
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Figure 3. DDX5 Depletion Induces Apoptosis
in AML Cells that Can Be Blocked by BCL2
Overexpression
(A) Immunoblot analysis of whole-cell extracts (WCEs)
from doxycycline-treated RN2 cultures at increasing
time after doxycycline treatment. The DDX5 shRNA
tested was shDDX5.2086, and the control shRNA is
shRen.713.
(B) Immunoblot analysis similar to (A), except that the
RN2 cells were induced to express shDDX5.2086 in
the presence (MSCV-Bcl2) or absence (MSCV-
Empty) of BCL2 overexpression.
(C) Plot showing the percentage of apoptotic cells
(Annexin V positive) in the indicated RN2 cultures with
or without BCL2 overexpression. All cultures were
treated with doxycycline to induce expression of the
indicated shRNAs. Data are presented as the mean
from triplicate samples with SD shown. The blue bar
shows results for cells overexpressing BCL2, and the
red bars show results for cells not overexpressing
BCL2.
(D) Competition cell proliferation assay for LG1 cells
constitutively expressing the indicated shRNAs with
or without BCL2 overexpression. Data are presented
as the mean from triplicate samples with SD shown.transgenes, suggesting that DDX5 overexpression in AML cells
was not tolerated. Furthermore, whereas we were able to obtain
RN2 AML cells resistant to the antibiotic selection marker
(puromycin) coexpressedwith theDdx5 transgenes, immunoblot
analysis failed to reveal HA-tagged DDX5 protein expression
(Figure S3C). Despite our inability to detect the HA-DDX5 protein
in these cells, increased Ddx5 transcript in cells transduced with
the HA-Ddx5 transgenes was clearly detected (Figure S3D).
These results indicate that DDX5 protein level is tightly regulated
in AML where overexpression or inhibition of DDX5 expression
has deleterious consequences with AML cell proliferation.
Inhibition of DDX5 Expression Induces Oxidative Stress
in AML Cells
RNA sequencing (RNA-seq) analyses of gene expression
changes at time points prior to and concurrent with activation
of apoptotic signaling following DDX5 knockdown were per-
formed to gain insight into how DDX5 depletion slows AML cell
proliferation and induces apoptosis. Expression changes were
measured at both 24 and 48 hr following induction of DDX5
shRNA expression in RN2 cells. These were time points that cor-
responded tomaximal DDX5 knockdown and preceded the 72 hr
time point when depletion of RN2 cells with DDX5 knockdown
first became evident in cell cultures (Figures 3A and 3D).
Genes exhibiting greater than 1.5-fold change in expression in
RN2 cells with DDX5 knockdown with either of the two different
DDX5 shRNAs compared to RN2 cells expressing the control
shRen.713 shRNA were identified. Poorly expressed genes
with RPKMs (reads per kilobase per million reads) values of three
or less were excluded from this analysis. At 24 hr following DDX5Cell Reports 7, 1887–1shRNA induction, there were 125 differen-
tially expressed genes for the shDDX5.1322
versus shRen.713 triplicate and 104 differ-entially expressed genes for the shDDX5.2086 versus shRen.713
triplicate where the 2 gene lists shared 61 overlapping genes
(Table S1). At 48 hr following induction of DDX5 shRNA expres-
sion, there were 349 differentially expressed genes for the
shDDX5.1322 versus shRen.713 triplicate and 318 differentially
expressed genes for the shDDX5.2086 versus shRen.713 tripli-
cate where these 2 gene lists shared 236 overlapping genes
(Table S2). Thus, considerable overlap in differentially expressed
genes was observed following knockdown of DDX5with either of
the two different DDX5 shRNAs.
Previously, we analyzed gene expression changes in the
human colorectal cancer cell line, HCT116 (Mazurek et al.,
2012), that overexpressed DDX5 compared to colon epithelial
cells (Shin et al., 2007). We compared the genes whose expres-
sionwas consistently affected by either of the two different DDX5
shRNAs at either 24 or 48 hr after DDX5 knockdown with the
genes whose expression was significantly affected by DDX5
knockdown in HCT116 cells also at 24 and 48 hr after DDX5
knockdown and found only 9 overlapping genes at 24 hr (Fig-
ure S4A, top) and 15 overlapping genes at 48 hr (Figure S4A,
bottom). This modest overlap at both time points indicated that
DDX5 regulates the expression of different genes in different
cancer cells.
Two different types of analyses were performed on the RNA-
seq data. First, processes enriched in the differentially
expressed genes resulting from DDX5 knockdown were deter-
mined using Gene Ontology (GO) groups with between 10 and
100 genes (2,800 GO groups). For this analysis, the ‘‘ROC’’
(receiver operator characteristic) method for ermineJ across
the differential expression q values was applied for each data899, June 26, 2014 ª2014 The Authors 1891
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Figure 4. Inhibition of DDX5 Expression
Downregulates the Expression of Glucose
Metabolism Genes and Elevates ROS to
Induce Apoptosis
(A) Enrichment analysis indicating biological pro-
cesses enriched for genes differentially expressed
as a consequence of DDX5 knockdown in AML
cells. Only pathways scoring an FDR of <0.01 in
this analysis are shown.
(B) Flow cytometry analysis of levels of ROS in
AML (left plot) or MEF (right plot) cells with or
without DDX5 knockdown using a ROS-activated
fluorescent compound (CellROX; BD Bio-
sciences). The black line shows results for cells
expressing the control shRen.713 shRNA, the red
line shows results for cells expressing the
shDDX5.2086 shRNA, and the blue line shows
results for cells expressing the shDDX5.1322
shRNA.
(C) Immunoblot analysis of RN2 WCEs with or
without DDX5 knockdown either treated or un-
treated with 5 mM NAC.
(D) Flow cytometry analysis of apoptotic cells
(Annexin V positive) in AML cell cultures with or
without DDX5 knockdown with or without 5 mM
NAC. Data are presented as the mean from tripli-
cate samples with SD shown.set (Gillis et al., 2010). At the 24 hr time point, specific enrich-
ment for both DDX5 shRNAs compared to the shRen.713 control
was obtained for the GO process ‘‘negative regulation of
myeloid cell differentiation’’ (false discovery rate [FDR] <0.05).
At the 48 hr time point with an FDR cutoff of 0.05, 20 GO
processes significantly enriched for both DDX5 shRNAs were
observed (Table S3). Applying an FDR cutoff of 0.01, enrichment
for only metabolic functions was seen, suggesting that this is a
robust and specifically characteristic observation (Figure 4A).
In most cases, expression of metabolic genes was downregu-
lated, suggesting metabolic stress in AML cells with DDX5
knockdown.
In addition to the enrichment analysis, coexpression network
analysis was performed on the genes differentially expressed
following DDX5 knockdown (see Supplemental Experimental
Procedures and Figure S5). Enrichment analysis is dependent
on prior characterization of gene function, and the annotated
functions of genes may be biased by prior interest. Coexpres-
sion network analysis offers an alternative approach to deter-
mine whether differentially expressed genes resulting from
DDX5 knockdown have a shared property independent of prior
annotation of gene function by determining whether these
genes exhibit similar expression profiles (coexpression). Our
analysis revealed that the differentially expressed genes result-
ing from DDX5 knockdown preferentially clustered with a
cancer gene coexpression network compared to a brain-based
gene coexpression network (Figure S5B, ROC difference 0.1).
This analysis indicated that DDX5 regulated the expression of
genes much more relevant to cancer than normal cells such
as neurons. Moreover, this entirely orthogonal mode of analysis
to the enrichment analysis revealed enrichment for genes
involved in monosaccharide metabolic process and hexose
metabolic process in the tail end of the distribution of ROC1892 Cell Reports 7, 1887–1899, June 26, 2014 ª2014 The Authorsdifferences in Figure S5B (ROC difference >0.05) Thus, gene
expression analysis using two orthogonal approaches pointed
to cell metabolism as a process influenced by DDX5
knockdown.
Metabolic stress can alter cellular reduced nicotinamide
adenine dinucleotide phosphate production affecting the redox
environment in the cell to trigger an increase in reactive oxygen
species (ROS) levels and induce an apoptotic response (Ander-
sen and Kornbluth, 2013). DDX5 regulation of cell metabolism
genes suggested that DDX5 knockdown might trigger an in-
crease in ROS levels in AML cells to promote apoptosis. Indeed,
ROS levels were elevated in AML cells after DDX5 knockdown
(Figure 4B). Importantly, the elevated ROS level was sufficient
to induce apoptosis because treating the AML cells with the
exogenous ROS scavenger N-acetyl-L-cysteine (NAC) blocked
induction of apoptosis in DDX5-depleted AML cells (Figures 4C
and 4D).
In addition to apoptosis, increased ROS levels can also induce
AML cells to differentiate (Callens et al., 2010). The effect of
DDX5 knockdown on differentiation of AML cells was tested by
comparing gene expression changes in the RN2 cells after
DDX5 knockdown with gene expression changes in these cells
following either withdrawal of expression of the Mll-Af9 onco-
gene (Zuber et al., 2011a) or BRD4 knockdown (Zuber et al.,
2011b), the consequences of which have been shown to induce
differentiation of these cells. We found very little overlap for
genes affected by DDX5 knockdown (Figure S4B, top and
bottom), which is inconsistent with DDX5 knockdown activating
a differentiation gene expression signature. Moreover, DDX5
knockdown did not alter RN2 cell morphology or affect the
expression of surface markers indicative of differentiation (Fig-
ures S4C and S4D). Thus, DDX5 depletion activated apoptosis
and did not promote myeloid cell differentiation.
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Figure 5. Combined Inhibition of DDX5 and BCL2 Family Proteins Cooperates to Induce Apoptosis in THP1 AML cells
(A) Immunoblot analysis of BCL2 family proteins in WCEs from the indicated AML cell lines. Note that WCEs prepared from 50,000 cells per cell line were loaded
onto the immunoblots, and results for triplicate independently prepared WCEs from each cell line are presented.
(B) Immunoblot analysis of caspase-3 activation for THP1 cells with or without DDX5 knockdown treated for 24 hr with increasing concentration of ABT-737.
Concentrations of ABT-737 tested were 0, 0.1, 0.5, 1, 5, and 10 mM.
(C) Flow cytometry analysis of live GFP-positive cells in THP1 cultures with or without DDX5 knockdown untreated or treated for 24 hr with either low-dose
(0.5 mM) or high-dose (5 mM) ABT-737. Results from duplicate cultures per RNAi condition are presented. GFP-positive cells were gated, and the percentage of
GFP-positive cells in each culture is shown.Inhibition of DDX5ExpressionCooperateswith ABT-737
to Kill AML Cells
Because BCL2 is frequently overexpressed in AML (Tzifi et al.,
2012), we considered whether a DDX5 requirement for AML
cell survival might inversely correlate with BCL2 levels. DDX5
knockdown in MV4-11 cells resulted in apoptosis (Figure S6A),
whereas DDX5 knockdown in THP1 cells did not (Figure 5B,
lane 1). Similar to the RN2 AML cell line, DDX5 knockdown in
MV4-11 cells induced apoptosis but did not activate a p53
response (Figure S6B). Interestingly, both BCL2 and MCL1 are
overexpressed in THP1 cells compared to MV4-11 cells (Fig-
ure 5A). It is noteworthy though that DDX5 knockdown still
impaired THP1 cell proliferation (Figure 1), mirroring our results
with RN2 cells we engineered to overexpress BCL2 (Figure 3D).
We next considered whether inhibiting BCL2 function might
sensitize THP1 cells to undergo apoptosis following DDX5
knockdown. ABT-737 is a BH3 mimetic compound that blocks
the interaction of pro- and antiapoptotic BCL2 family proteinsCto result in an apoptotic response in the presence of proapopto-
tic signaling (Cory and Adams, 2005; Oltersdorf et al., 2005). The
BCL2 family inhibitor, ABT-737, was titrated onto THP1 cells with
or without DDX5 knockdown (shDDX5.2053 versus the negative
control shRen.713; Figure 5B). Combining DDX5 knockdown
with ABT-737 resulted in apoptosis at a much lower dose of
ABT-737 (0.5 mM) compared to THP1 cells treated with ABT-
737 alone (5 mM). Moreover, combining DDX5 knockdown with
ABT-737 treatment resulted in substantially fewer GFP-positive
live cells within 24 hr of drug treatment compared to ABT-737
treatment alone (Figure 5C). We conclude that DDX5 knockdown
induces an apoptotic signal in THP1 cells that is blocked by
BCL2.
DDX5 Knockdown Is Well Tolerated in Normal Adult
Tissues
DDX5 depletion blocks the proliferation of colon and breast
cancer cells (Mazurek et al., 2012) and induces apoptosis inell Reports 7, 1887–1899, June 26, 2014 ª2014 The Authors 1893
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Figure 6. DDX5 Knockdown in Adult Mice Is Well Tolerated
(A) Immunoblot analysis of the indicated proteins in WCEs prepared from the noted organs of duplicate mice either treated (On-Dox, lanes 1 and 2) or untreated
(Off-Dox, lanes 3 and 4) with doxycycline to induce shRNA expression. WCEs prepared from the organs of the fourth Off-Dox mouse are loaded on each blot
either with equal total protein loading as the WCEs from the other mice (lane 4) or they were diluted 1:2 (lane 5), 1:4 (lane 6), or 1:10 (lane 7).
(B) Representative tissue sections obtained frommice with or without doxycycline stained to detect DDX5 protein. The brown staining marks DDX5 protein in the
tissues. For the ON-DOX mice presented in both (A) and (B), the organs were dissected after 2 weeks of continuous doxycycline to induce shRNA expression.
(legend continued on next page)
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T-ALL (Lin et al., 2013) and AML cells. However, it is unclear
whether normal adult tissues will be similarly sensitive to inhibi-
tion of DDX5 expression. A Ddx5 knockout is incompatible with
embryonic development (Fukuda et al., 2007), and Ddx5 inacti-
vation by Cre-mediated gene excision in adult mice was re-
ported to lead to apoptotic cells in the bone marrow and altered
tissue organization of the large intestine (Nicol et al., 2013). How-
ever, the long-term consequences of systemic DDX5 suppres-
sion on normal physiology have not been thoroughly examined.
Transgenicmicewith doxycycline-inducible, systemic expres-
sion of a potent DDX5 shRNAwere developed to test the effect of
DDX5 depletion in adult tissues. This method allows reversible
gene knockdown in normal tissues of an adult mouse followed
by monitoring for adverse consequences (Dow et al., 2012).
The DDX5 shRNAwas cloned into the 30 UTR of aGfp transgene,
and expression of both GFP and the shRNA was induced in
tissues by giving the transgenic mice doxycycline in their
food and water. To generate the transgenic DDX5 shRNA
mice, clonal lines of KH2 mouse embryonic stem (ES) cells
(Beard et al., 2006) encoding the rtTA at the Rosa26 enhancer
and shDDX5.2086 in the Col1A1 locus were established and
tested for doxycycline-induced GFP expression and DDX5
knockdown in vitro. An ES cell clone was selected that showed
tight doxycycline-induced GFP expression and greater than
10-fold DDX5 knockdown (Figure S7A). Using tetraploid embryo
complementation, founder mice were derived from the ES cell
clone, and these mice were subsequently bred (Figure S7B) to
obtain mice homozygous for both the Rosa26-rtTA allele and
Col1A1-shDdx5.2086 allele (Rosa26-rtTA+/+ and Col1A1-
shDdx5.2086+/+). The mice were bred in the absence of doxycy-
cline, and they yielded pups with the expected Mendelian
ratios for the Rosa26-rtTA and Col1A1-shDdx5.2086 alleles. At
8–12 weeks of age, the mice were separated into two groups
where one group was given a normal diet and the second group
was given water and food containing doxycycline to induce
DDX5 shRNA expression.
After 2 weeks of doxycycline treatment, several mice were
sacrificed and their organs dissected for analysis. Immunoblots
showed strong doxycycline-induced GFP expression as well as
4- to >10-fold knockdown of DDX5 in whole-cell extracts pre-
pared from bone marrow, intestine, skin, liver, thymus, and
pancreas (Figures 6A and S7C). Immunohistochemical analysis
of DDX5 in these tissues revealed the expected strong nuclear
staining for DDX5 that was ubiquitous in the organs dissected
from animals fed the doxycycline-free diet (Figures 6B and
S7D). This DDX5 signal was largely depleted in most cell types
that comprise these tissues dissected from mice fed doxycy-
cline. Western blot analysis of tissue extracts revealed that
DDX5 knockdown was particularly strong (greater than 10-fold
in the organ as a whole) in the intestine, bone marrow, thymus,
and pancreas. In the small intestine, DDX5 depletion was evident
in the nuclei of cells that comprise both the villi and the crypts of
Lieberkuhn (Figure S8). In liver, DDX5 knockdown was strong in(C) Weight measurements of mice either given or not given doxycycline that were
(n = 6 for each genotype/doxycycline group) with SD shown.
(D) Flow cytometry analysis of GFP-positive DDX5 shRNA expressing peripheral b
Data are presented as the mean from duplicate mice with SD shown.
Chepatocytes but weak in Kupffer cells. Hence, the 4- to 10-fold
depletion of DDX5 observed in the immunoblot analysis of these
tissues may be an underestimate of DDX5 knockdown in a
particular cell type. DDX5 knockdown in heart and lung was
generally weak by both immunoblot (Figure S7C) and immuno-
histochemical analysis (Figure S7D).
Mice were maintained on doxycycline for 2 months, and their
weights were recorded to determine whether DDX5 depletion
caused changes in weight, an indicator of stress. As an addi-
tional control, we included doxycycline-fed mice that were
homozygous for the Rosa26-rtTA allele but negative for the
Col1A1-shDdx5.2086 allele (Figure 6C, No shRNA indicates
Rosa26-rtTA+/+ and Col1A1-shDdx5.2086/). Mice with DDX5
depletion continued to gain weight over 2 months of knockdown
similar to Rosa26-rtTA+/+, Col1A1-shDdx5.2086+/+ mice not
given doxycycline or the control No shRNA mice that were given
doxycycline (Figure 6C). We also analyzed peripheral blood
leukocytes to determine whether 10-fold DDX5 knockdown in
the bone marrow had an adverse effect on white blood cell pro-
duction. GFP was tested as a surrogate marker of DDX5 shRNA
expression in the different leukocyte subpopulations. If DDX5
depletion adversely affected the differentiation of leukocytes,
then over time of doxycycline treatment, it was expected that
the GFP-positive cells in the affected leukocyte subpopulation
would be depleted from peripheral blood, presumably because
precursor cells that lack GFP expression and DDX5 knockdown
would outcompete. The fraction of GFP-positive leukocytes in
peripheral blood from mice treated with doxycycline for either
1 or 5 weeks showed no reduction in the percentage of GFP-
positive peripheral blood leukocytes (Figure 6D). The lack of
depletion of GFP-positive leukocytes indicated normal bone
marrow function in the mice despite >10-fold DDX5 knockdown
in the bone marrow.
The impact of >10-fold DDX5 knockdown on bone marrow
function was further tested by depleting DDX5 in mice given
doxycycline for 2 weeks, then irradiating the mice with a high
irradiation (IR) dose (550 Rad). Mice were sacrificed shortly after
IR, and their bone marrow was analyzed for apoptotic cells.
DDX5 inactivation was reported to increase the signal for both
p21 and cleaved caspase-3 in the bone marrow following
DDX5 ablation (Nicol et al., 2013). However, in our experiments,
neither immunoblot nor immunohistochemical analysis indicated
increased p21 or caspase-3 activation in the bone marrow
harvested from mice with DDX5 knockdown in the absence of
IR (Figures 7A and 7B). As expected, IR strongly induced both
p21 expression and caspase- 3 activation, regardless of DDX5
expression status. Importantly, mice with DDX5 knockdown
recovered from IR similar to littermate controls with normal
DDX5 expression (Figure 7C). Moreover, immunoblot analysis
of DDX5 protein abundance in whole-cell extracts prepared
from bone marrow 28 days following IR retained the 10-fold
knockdown of DDX5 similar to mice that were not irradiated (Fig-
ure 7D). These data indicate that 10-fold DDX5 depletion did notmeasured over 2 months. Data are presented as the mean from multiple mice
lood leukocytes at either 1 or 5 weeks of continuous doxycycline administration.
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Figure 7. DDX5 Depletion Does Not Impair
Mouse Recovery from Stress Caused by
High-Dose IR
(A) Representative tissue sections obtained from
mice with or without doxycycline with or without IR
with 550 Rad. Tissue samples were collected 4 hr
after IR and stained for the indicated proteins.
(B) Immunoblot analysis of WCEs prepared from
bone marrow of mice with or without doxycycline
with or without IR (4 hr post-IR).
(C) Weight measurements of mice with the indicated
genotypes with or without doxycycline with or
without IR every other day for 1 month following IR.
Results for irradiated mice are indicated by ‘‘X’’
labels, and results for nonirradiated mice are
indicated with closed diamonds. Results for
shDDX5.2086 mice on doxycycline are color-coded
red, results for shDDX5.2086 mice off doxycycline
are color-coded blue, and results for no shRNA
mice are color-coded green. Data are presented as
the mean from multiple mice (n = 4 for each geno-
type with or without doxycycline with or without IR)
with SD shown.
(D) Quantitative immunoblot analysis of DDX5 in
WCEs prepared from bone marrow collected from
duplicate mice with or without doxycycline with or
without IR at either 4 hr after IR (upper blot) or
28 days after IR (lower blot). In both blots, bone
marrow WCEs from the second irradiated mouse
that was not given doxycycline were loaded at either
equivalent total protein as the other bone marrow
WCEs (lane 8) or was diluted 1:2 (lane 9), 1:4 (lane
10), or 1:10 (lane 11).adversely affect normal bone marrow function or adult mouse
physiology.
DISCUSSION
Current AML therapy consists of an induction phase that typi-
cally includes the cytotoxic compound cytarabine in combina-
tion with an anthracycline such as daunorubicin or idarubicin. If
the induction phase results in complete remission, then it is
followed with a consolidation therapy phase also consisting of
cytotoxic chemotherapy. In addition to killing leukemia cells,
these agents also kill rapidly dividing normal cells to cause sub-
stantial side effects. The limited efficacy of this therapeutic
approach is evident in that patients 56 years or older with AML
have a 2-year survival rate of 20%–25% (Estey and Do¨hner,
2006). Our study demonstrates an important activity for DDX5
in the proliferation and survival of AML cells in vitro and in vivo,
including AML cell lines that are dependent on multiple different
oncogenic driver mutations. Importantly, DDX5 depletion was1896 Cell Reports 7, 1887–1899, June 26, 2014 ª2014 The Authorswell tolerated in normal adult tissues
in vivo, suggesting that therapeutic ap-
proaches targeting DDX5 might be effec-
tive in blocking genetically diverse AML
and be well tolerated and safe.
One approach to block DDX5 activity in
AML could be with small molecule com-pounds that inhibit the DDX5 ATP-dependent RNA helicase
activity. However, DDX5 shares strong sequence identity with
another closely related DEAD-box RNA helicase, DDX17, pre-
senting a significant challenge for identifying DDX5-specific in-
hibitors. Strategies that disrupt key protein-protein interactions
offer an alternative approach. In fact, in two cases where the
oncogenic activity of DEAD-box proteins or related DEXH-box
proteins have been targeted, the compounds antagonize pro-
tein-protein interactions required for cancer cell proliferation/
survival. Silvesterol inhibits free EIF4A (DDX2A) assembly into
the EIF4F complex to reduce translation of proteins required
for tumorigenesis (Cencic et al., 2009). Compound YK-4-279 dis-
rupts an interaction between the EWS-FLI1 oncogenic fusion
protein and RNA helicase A (DHX9) and induces apoptosis in
Ewing’s sarcoma family tumor cells (Erkizan et al., 2009). Further
investigation to identify important protein-protein interactions
that underlie the acquired dependence of AML cells and other
cancer cells on DDX5 may reveal interactions amenable for tar-
geting by small molecule inhibitors as well as provide more
mechanistic insights into why these cancers are sensitive to
DDX5 depletion.
Mutations that repress expression of differentiation genes or
that increase the expression of genes to support aberrant self-
renewal contribute toward AML pathogenesis. One example
is the MLL-AF9 fusion protein that is the product of the
t(9;11)(p22;q23) chromosomal translocation. Withdrawal of
MLL-AF9 expression in a mouse model of MLL-AF9-dependent
AML resulted in induction of differentiation and blockage of
AML progression in vivo (Zuber et al., 2011a). A similar outcome
was observed when the BET family protein BRD4 was blocked
either by RNAi or pharmacologically (Zuber et al., 2011b). In
contrast, DDX5 depletion induced apoptosis and blocked AML
proliferation without inducing differentiation. Thus, DDX5 deple-
tion illuminatesanalternative vulnerability inAML to targeted ther-
apy and suggests that combined inhibition of BET family proteins
and DDX5may synergize to kill AML cells. This is underscored by
the finding that BCL2 expressionwas downregulated by pharma-
cologic inhibition of BET family proteins in AML (Dawson et al.,
2011), and thus, BET family inhibitors may cooperate with DDX5
inhibition to kill AML cells, similar to BCL2 family inhibitors.
Consistent with our findings in AML cells, DDX5 knockdown in
T-ALL cells also results in impaired cell proliferation and induc-
tion of apoptosis (Lin et al., 2013). However, in T-ALL, DDX5
functions as a transcriptional coactivator of NOTCH-dependent
gene expression via its interaction with MAML1. Thus, DDX5
knockdown impacts the expression of different genes in different
cancer contexts. Indeed, we observed very little overlap
between genes downregulated by DDX5 knockdown in the
RN2 AML cell line compared to the epithelial colorectal cancer
cell line, HCT116. Independent of mechanism, however, the
combined results suggest DDX5 as a therapeutic target for
some epithelial cancers as well as hematologic malignancies
including AML and potentially T-ALL.
The transgenic shRNA approach we applied enables assess-
ment of the therapeutic index for blocking the activity of a candi-
date drug target such as DDX5. This approach was successfully
applied to study the dependence of adult mouse physiology on
the expression of essential genes such as Rpa3, encoding the
essential single-stranded DNA binding protein subunit (McJun-
kin et al., 2011). Systemic RPA3 knockdown caused dramatic
organ degeneration and was fatal within 8–10 days following
RPA3 shRNA induction.
DDX5 is required for development because Ddx5 knockout
mouse embryos fail to develop beyond embryonic day 11.5 (Fu-
kuda et al., 2007). Conditional, systemic Ddx5 knockout in adult
mice was reported to increase apoptosis in bone marrow,
reduce clonogenic survival of blasts derived from bone marrow,
and alter organ morphology in the large intestine (Nicol et al.,
2013). In contrast, 4- to 10-fold inhibition of DDX5 expression
in multiple organs of the transgenic DDX5 shRNAmice, including
organs with a high rate of cell proliferation such as bone marrow,
intestine, and skin, resulted in no adverse consequences on
organ morphology, and these mice continued to gain weight
normally over the 6-month duration. Importantly, 10-fold DDX5
knockdown in the bone marrow did not induce detectable
apoptosis or impair bone marrow function, even after high-
dose IR. The differences in outcomes of DDX5 depletion in theCbone marrow between our study and the Nicol et al. (2013) study
may be due to the remaining 10%DDX5 expression in our trans-
genic mice or could be due to differences between our methods
for blocking DDX5 expression. For example, Cre-mediated
recombination may potentially cause DNA damage and produce
a phenotype independent of DDX5 depletion. Moreover, the
altered tissue organization reported by Nicol et al. (2013) in the
large intestines of mice with Ddx5 knockout appears to have
been misinterpreted.
The observations reported here provide a comprehensive pro-
cedure to identify and validate an antitumor therapeutic target
and at the same time assess the impact of the anticancer therapy
on normal tissues. DDX5 depletion selectively induces stress in
AML cells and delays AML progression in vivo but is well toler-
ated by normal adult physiology. We have also identified a
potential mechanism of resistance to anti-DDX5 therapy,
because BCL2 is frequently overexpressed in AML (Tzifi et al.,
2012) and BCL2 overexpression prevents apoptosis induced
by DDX5 knockdown. But the results further suggest that combi-
nation therapy that blocks bothDDX5 andBCL2may be effective
in AML that is refractory to current treatments.
EXPERIMENTAL PROCEDURES
For a detailed description of cell lines, plasmids, antibodies, shRNAs, and
protocols, see Supplemental Experimental Procedures. Plasmids encoding
N-terminal HA-tagged or 6myc-tagged DDX5 that we used to generate
RNAi-resistant wild-type and mutant HA-tagged DDX5 transgenes presented
in Figure S5 were kindly provided by Dr. Ralf Janknecht (Shin et al., 2007).
Preparation of Cell Lines with Either Constitutive or Inducible
shRNA Expression
Cell lines with either constitutive or inducible shRNA expression were prepared
using retroviral infection. Details including retroviral packaging and cell infec-
tions are described in the Supplemental Experimental Procedures.
Competition Cell Proliferation Assay
To measure the effect of DDX5 knockdown on cell proliferation, infected AML
cells were not selected following infection with virus encoding constitutive
expression of the indicated shRNAs. These viruses also encode constitutive
GFP expression, so the fate of infected GFP-positive cells expressing the
shRNAs was tracked in unselected cell cultures by analysis on a Guava easy-
Cyte 8HT flow cytometer (Millipore). Infections typically yielded 10%–20%
infected cells for each cell line except LG1 and MEF cells, where infection
efficiency was 70%–90%. The GFP-positive populations in each culture
were measured each day following infection, and recording of the GFP-posi-
tive populations was begun when GFP expression in each culture was
maximum, which was typically 2 days (for LG1 and MEF cells) and 4 days
(for human AML cell lines) following infection. This is indicated as day 0 on
the plots shown in Figures 1, 2A, 3D, S1A, S1B, and S2D. The percent GFP-
positive cells observed on each following day were then normalized to these
percent GFP-positive cells on day 0 for each cell line.
In Vivo Mouse Experiments
The Cold Spring Harbor Laboratory animal care and use committee approved
all mouse experiments. The in vivo AML experiment was performed as
described by Zuber et al. (2011b). For a detailed description of the in vivo
AML experiments and also generation of transgenic DDX5 shRNA mice, see
Supplemental Experimental Procedures (Dow et al., 2012; Zuber et al.,
2011b). To induce shRNA expression in either the transplanted AML cells in
the in vivo AML experiment or the transgenic DDX5 shRNA mice tested in the
safety studies, doxycycline was provided to the mice in their drinking water
(containing 2 mg/ml doxycycline [Sigma-Aldrich; D-9891] with 2% sucrose)ell Reports 7, 1887–1899, June 26, 2014 ª2014 The Authors 1897
and in their food (625 mg/kg; Harlan Laboratories). Mice tested in the in vivo
AML experimentwere given doxycycline food andwater 5 days after transplan-
tation with AML cells and were maintained on doxycycline food and water for
the duration of the experiment. For the safety studies, 8-to-12-week-old trans-
genic DDX5 shRNAmicewere given doxycycline-containing food andwater for
2–4 weeks to induce DDX5 knockdown, then doxycycline food with doxycy-
cline-freewater thereafter tomaintainDDX5knockdown. For the IRexperiment,
themicewere given doxycycline-containing food andwater for 2weeks prior to
IR, then were maintained on doxycycline food and water for the 28-day follow-
up after IR.
Apoptosis and ROS Measurements in RN2 Cells
For analysis of apoptotic AML cells, the cells were stained with Pacific Blue-
conjugated anti-Annexin V (BioLegend, catalog no. 640917) and 7-AAD
(BioLegend, catalog no. 420401) as per the manufacturer’s protocol. Sample
analysis was performed on an LSRII flow cytometer (BD Biosciences) using
FACSDiva software. Annexin V-positive/7-AAD-negative cells in each cell
suspension were recorded as the early apoptotic cell fraction. For analysis
of ROS levels in AML cells following 3 days of doxycycline-induced shRNA,
two million cells per suspension were treated for 30 min at 37C with CellROX
Deep Red Reagent (Life Technologies, catalog no. C10422). The cells were
then processed for flow cytometry analysis using the manufacturer’s protocol.
Analysis was performed on the LSRII flow cytometer, and viable cells in each
suspension were gated for analysis of CellROX fluorescence.
Cell Viability Measurements in THP1 Cells
Tet-On THP1 cells with doxycycline-inducible expression of either
shDDX5.2053 or shRen.713 were prepared by infecting Tet-On THP1 cells
that stably expressed rtTA (Zuber et al., 2011b) with virus packaged with either
the pTRIN-shDDX5.2008 or pTRIN-shRen.713-packaging plasmids. Infected
cells were selected in RPMI plus 10% fetal bovine serum (FBS) plus 1 mg/ml
G418. Expression of the shRNAs in the derivative Tet-On THP1 cell lines
was then induced in RPMI plus 10% FBS plus 1 mg/ml G418 plus 1 mg/ml
doxycycline. After 12 days of shRNA expression, onemillion Tet-On THP1 cells
expressing the different shRNAs were seeded to new wells of 6-well tissue
culture plates in 4 ml RPMI plus 10% FBS plus 1 mg/ml G418 plus 1 mg/ml
doxycycline plus the indicated concentrations of ABT-737 (http://www.
selleckchem.com; catalog no. S1002) dissolved in DMSO. Cultures not treated
with ABT-737 were treated with an equivalent volume of DMSO. Samples were
prepared for immunoblot and flow cytometry analysis 24 hr after ABT-737
treatment. For flow cytometry analysis, cells in each culture were washed
twice in 13 PBS, then GFP-positive cells suspended in 13 PBS from each cul-
ture were measured using an LSRII flow cytometer.
RNA-Seq Experiment
DDX5 was knocked down in RN2 AML cells by doxycycline-induced expres-
sion of either shDDX5.1322 or shDDX5.2086. For control, expression of the
shRen.713 shRNA was similarly induced in RN2 AML cells. At 24 and 48 hr,
RNA was isolated, and bar-coded cDNA libraries were prepared as described
in Supplemental Experimental Procedures. The resulting 18 bar-coded cDNA
libraries were pooled into 3 pools of 6 cDNA libraries each, and then each pool
was loaded onto 2 lanes of an Illumina HiSeq 2000 sequencer on which paired-
end 101 sequencing runs were performed. Processing and mapping of the
reads are described in the Supplemental Experimental Procedures (Gillis
and Pavlidis, 2011).
ACCESSION NUMBERS
The reported data have been deposited in NCBI’s Gene Expression Omnibus
(GEO) under accession number GSE53599.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
eight figures, and three tables and can be found with this article online at
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